[New drug forms of isosorbide dinitrate: the problem of an objective evaluation in patients with ischemic heart disease].
In 7 patients with ischemic heart disease and stable angina pectoris the efficacy of three oral isosorbide dinitrate (ID) formulations, nitrosorbide, isodinite and isodinite-retard, was compared. The antianginal and anti-ischemic effects were assessed in terms of exercise treadmill tests performed prior to and repeatedly after (2, 5 and 7 hours) single-dose administration (in comparison with placebo). The efficacy of isodinite-retard only slightly differed from that of placebo. Isodinite had a more pronounced effect than nitrosorbide, although the duration of isodinite effect was shorter than that of nitrosorbide. Plasma ID and its metabolite, isosorbide-5-mononitrate concentrations mirrored exercise duration changes. ID content in the tablets of all formulations studied corresponded to those indicated by the manufacturer. The differences in the efficacy of ID formulations can be attributed to the differences in their bioavailability. Thus, the method used permitted to reveal significant distinctions in the efficacy of different ID formulations. These distinctions must be taken into account in clinical practice.
S Iu
SIu
Martsevich
V I
VI
Metelitsa
M P
MP
Kozyreva
S V
SV
Blagodatskikh
L S
LS
Simkhaev
V K
VK
Piotrovskiĭ
D000787:Angina Pectoris / Q000097:blood / Q000188:drug therapy; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005080:Exercise Test; D006801:Humans; D007548:Isosorbide Dinitrate / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D013607:Tablets; D013810:Therapeutic Equivalency
D003692:Delayed-Action Preparations; D013607:Tablets; D007548:Isosorbide Dinitrate
Novye lekarstvennye formy izosorbida dinitrata: problema ob''ektivnoĭ otsenki u bol'nykh ishemicheskoĭ bolezn'iu serdtsa.